









Markets
/
Stocks
/
nasdaq-vrna
/

Verona Pharma PLC

VRNA

View Detailed Chart

92.200USD

-0.295-0.32%

Close 06/13, 16:00（ET）Quotes delayed by 15 min

62.79BMarket Cap

LossP/E TTM



Verona Pharma PLC

92.200

-0.295-0.32%

Company

Intraday

30m

Today

-0.32%

5 Days

+9.32%

1 Month

+37.12%

6 Months

+122.60%

Year to Date

+98.54%

1 Year

+508.98%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 11 analysts

BUY

Current Rating

93.727

Target Price

1.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

557

Total

Median

Average

Company name

Ratings

Analysts

Verona Pharma PLC

VRNA

CRISPR Therapeutics AG

CRSP

Regeneron Pharmaceuticals Inc

REGN

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Moderna Inc

MRNA

...

112

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(0)

Buy(9)

Indicators

Sell(1)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

1.771

Buy

RSI(14)

78.052

Buy

STOCH(KDJ)(9,3,3)

87.083

Overbought

ATR(14)

3.339

High Vlolatility

CCI(14)

135.354

Buy

Williams %R

7.476

Overbought

TRIX(12,20)

1.123

Sell

StochRSI(14)

88.467

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

89.233

Buy

MA10

86.893

Buy

MA20

80.881

Buy

MA50

70.576

Buy

MA100

66.515

Buy

MA200

51.606

Buy

News

More news coming soon, stay tuned...

Company

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Ticker SymbolVRNA

CompanyVerona Pharma PLC

CEODr. David S. Zaccardelli

Websitehttps://www.veronapharma.com/